Drug Trial Radar · NCT02601703
To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)
Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,110
Actual
Start
Aug 2015
Primary completion
Oct 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. IndiaIndustry
- Sponsor type
- Industry
- First posted
- Nov 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmaceuticals, Ltd) to the Marketed Product Protopic® (tacrolimus) ointment, 0.1% (Astellas Pharma US, Inc.) in the Treatment of Moderate to Severe Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
Tacrolimus Ointment 0.1%Drug
apply thin layer of ointment to affected area
Protopic® ointment, 0.1%Drug
apply thin layer of ointment to affected area
Placebo of Tacrolimus OintmentDrug
apply thin layer of ointment to affected area
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's Global Assessment (IGA) score of 0 or 1 within all treatment areas at the end of treatmentTime frame: Day 15
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
Glenmark Investigational Site 49
Tempe, Arizona
Glenmark Investigational Site 31
Anaheim, California
Glenmark Investigational Site 23
Bell Gardens, California
Glenmark Investigational Site 30
Cerritos, California
Glenmark Investigational Site 15
Chula Vista, California
Glenmark Investigational Site 14
La Mesa, California
Glenmark Investigational Site 1
Long Beach, California
Glenmark Investigational Site 17
Oceanside, California
Glenmark Investigational Site 25
Pasadena, California
Glenmark Investigational Site 20
San Ramon, California
Glenmark Investigational Site 44
Santa Ana, California
Glenmark Investigational Site 45
Brooksville, Florida
Glenmark Investigational Site 43
Coral Gables, Florida
Glenmark Investigational Site 34
Doral, Florida
Glenmark Investigational Site 22
Fort Lauderdale, Florida
Glenmark Investigational Site 35
Hialeah, Florida
Glenmark Investigational Site 59
Hialeah Gardens, Florida
Glenmark Investigational Site 11
Miami, Florida
Glenmark Investigational Site 19
Miami, Florida
Glenmark Investigational Site 33
Miami, Florida
Glenmark Investigational Site 40
Miami, Florida
Glenmark Investigational Site 42
Miami, Florida
Glenmark Investigational Site 50
Miami, Florida
Glenmark Investigational Site 51
Miami, Florida
Glenmark Investigational Site 54
Miami, Florida
Glenmark Investigational Site 56
Miami, Florida
Glenmark Investigational Site 58
Miami, Florida
Glenmark Investigational Site7
Miami, Florida
Glenmark Investigational Site 28
Miami Gardens, Florida
Glenmark Investigational Site 29
Miami Lakes, Florida
Glenmark Investigational Site 18
Miramar, Florida
Glenmark Investigational Site 32
North Miami Beach, Florida
Glenmark Investigational Site 48
Orlando, Florida
Glenmark Investigational Site 4
Ormond Beach, Florida
Glenmark Investigational Site 47
Pembroke Pines, Florida
Glenmark Investigational Site 5
Winter Park, Florida
Glenmark Investigational Site 52
Macon, Georgia
Glenmark Investigational Site12
Madisonville, Kentucky
Glenmark Investigational Site 2
Saint Joseph, Missouri
Glenmark Investigational Site 41
Henderson, Nevada
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.